Business Context and Reporting Period
This Form 8-K was filed by Second Sight Medical Products, Inc. on February 8, 2018, reporting events as of February 5, 2018. The filing provides an operational update on key performance metrics as of January 31, 2018, focusing on the Argus II Retinal Prosthesis System and the Orion Cortical Visual Prosthesis System.
Key Financial and Operational Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on operational milestones:
- Implant Volume (2017): 75 total Argus II implants worldwide.
- Implant Volume (Q4 2017): 30 Argus II implants.
- Orion Progress: First human patient implanted in late January 2018.
- Reimbursement: Argus II reimbursement renewed in Germany for the 2018 calendar year (8th consecutive year).
Material Changes Versus Prior Period
Significant growth in implant volume was reported compared to the prior year:
- Q4 2017 vs. Q4 2016: Implants increased from 7 to 30, representing a 329% growth rate.
- Full Year 2017 vs. Full Year 2016: Implants increased from 42 to 75, representing a 79% growth rate.
- Expansion: A new Center of Excellence was added in Houston, TX, in early January 2018.
Guidance, Outlook, and Risks
Outlook and Clinical Progress:
- Enrollment of the first patient(s) for a clinical study involving better-sighted patients with Retinitis Pigmentosa (RP) in Germany is expected during Q1 2018.
- Two sites in Germany are actively screening subjects, with a third site expected to begin screening shortly.
Risks and Contingencies: The filing text does not explicitly detail new risks or contingencies beyond the standard nature of clinical studies and reimbursement renewals.
Key Facts for Investor Verification
- Verify the commercial impact of the 79% year-over-year increase in Argus II implants on future revenue recognition.
- Confirm the timeline and regulatory status of the Orion Cortical Visual Prosthesis System following the first-in-human implant.
- Monitor the enrollment progress of the Retinitis Pigmentosa clinical study in Germany expected in Q1 2018.
- Assess the financial implications of the renewed German reimbursement for the Argus II system.